HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Denis H. Tyras Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Graver, L. M. Articles by Tyras, D. H. Search for Related Content PubMed PubMed Citation Articles by Graver, L. M. Articles by Tyras, D. H.

Ann Thorac Surg 1988;46:85-88
© 1988 The Society of Thoracic Surgeons

---

Articles

The Risks and Benefits of Thrombolytic Therapy in Acute Aortic and Mitral Prosthetic Valve Dysfunction: Report of a Case and Review of the Literature

Division of Cardiothoracic Surgery, Long Island Jewish Medical Center, New Hyde Park, NY

Accepted for publication January 25, 1988.

^* Address reprint requests to Dr. Graver, The Heart Institute, Room 2123, Long Island Jewish Medical Center, New Hyde Park, NY 11042

A patient with acute thrombosis of a St. Jude mitral prosthesis was treated with streptokinase with initial success. Subsequent recurrent thrombosis and embolism prompted operative revision. Because the use of thrombolytic agents in this setting is somewhat controversial, we searched the literature for all reports of aortic or mitral prosthetic valve dysfunction treated this way. The cases of 58 patients treated 62 times were reviewed for efficacy of therapy and morbidity.

Thrombolytic therapy may be useful in patients with prosthetic valve thrombosis causing critical hemodynamic compromise. It is frequently the only treatment needed. Further, it may help reduce operative risk for those patients in whom complete resolution is not possible. The incidence of systemic embolism is 18%; however, neurological events are usually limited and transient.

This article has been cited by other articles:

				M M Yusuf, R A Archbold, A Wood, and D Dymond Paraprosthetic leak unmasked by thrombolysis for thrombosed mitral valve Heart, April 1, 2004; 90(4): e18 - 18. [Abstract] [Full Text] [PDF]

				J. Barbetseas, S. F. Nagueh, C. Pitsavos, P. K. Toutouzas, M. A. Quinones, and W. A. Zoghbi Differentiating thrombus from pannus formation in obstructed mechanical prosthetic valves: an evaluation of clinical, transthoracic and transesophageal echocardiographic parameters J. Am. Coll. Cardiol., November 1, 1998; 32(5): 1410 - 1417. [Abstract] [Full Text] [PDF]

				R. Manteiga, J. C. Souto, A. Altes, J. Mateo, A. Aris, J. M Dominguez, X. Borras, F. Carreras, and J. Fontcuberta Short-course thrombolysis as the first line of therapy for cardiac valve thrombosis J. Thorac. Cardiovasc. Surg., April 1, 1998; 115(4): 780 - 784. [Abstract] [Full Text] [PDF]

				T.-M. Lee, S.-H. Chu, L.-C. Wang, and Y.-T. Lee Thrombolysis for obstructed CarboMedics mitral valve prosthesis Ann. Thorac. Surg., February 1, 1995; 59(2): 509 - 511. [Abstract] [PDF]

				N. Vitale, A. Renzulli, F. Cerasuolo, A. Caruso, M. Festa, L. de Luca, and M. Cotrufo Prosthetic valve obstruction: Thrombolysis versus operation Ann. Thorac. Surg., February 1, 1994; 57(2): 365 - 370. [Abstract] [PDF]